Who
Warren Whitehead
Other role
Company insider
Files Form 4 as: Director and Other, Aptose Biosciences.
In numbers
- Trades disclosed
- 50
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $406K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 2 Jan 2019
- Last trade
- 30 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 1 Jul 2026 | Aptose BiosciencesBiotechnology | SEC FORM 4 Code D | $5733 at $1.72 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —53,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,333 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —3,333 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —152,500 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —40,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —53,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —152,500 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciences | SEC FORM 4 Code D | $5733 at $1.72 | filing |
News
No headline names them, or the companies they trade most, lately.